Should trichrome stain be used on all post-liver transplant biopsies with hepatitis c virus infection to estimate the fibrosis score?

Liver Transplantation

Volumn 14, Issue 5, 2008, Pages 695-700

  Tretheway, David ^a   Jain, Ashok ^a   LaPoint, Randi ^a   Sharma, Rajeev ^a   Orloff, Mark ^a   Milot, Patricia ^a   Bozorgzadeh, Adel ^a   Ryan, Charlotte ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; HEMATOXYLIN; TACROLIMUS;

ADULT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; STAINING; TRICHROME STAIN;

ADULT; AZO COMPOUNDS; BIOPSY; COLORING AGENTS; DISEASE PROGRESSION; EOSINE YELLOWISH-(YS); FEMALE; HEMATOXYLIN; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; METHYL GREEN; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 43849112591     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21422     Document Type: Article

References (25)

1. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-338.
2. Brown RS. Hepatitis C and liver transplantation. Nature 2005;436:973-978.
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation [see comment]. Gastroenterology 2002;122:889-896.
4. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322.
5. Gane EJ, Portmann BC. Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation [see comment]. N Engl J Med 1996;334:815-820.
6. Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994;20:1137-1143.
7. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al., for the European Concerted Action on Viral Hepatitis (EUROHEP) Group. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117:619-625.
8. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002;8:S14-S18.
9. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
10. Wiesner RH, Sorrell M, Villamil F, and International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1-S9.
11. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant 2006;6:449-458.
12. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002;8:1000-1006.
13. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [see comment]. Hepatology 1981;1:431-435.
14. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
15. Hubscher SG. Transplantation pathology. Semin Diagn Pathol 2006;23:170-181.
16. Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999;230:441-448.
17. Jain A, Mohanka R, Orloff M, Rohal S, Abu-Elmagd K, Starzl T, et al. Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation. Exp Clin Transplant 2005;3: 361-365.
18. Gomori G. A rapid one-step trichrome stain. Am J Clin Pathol 1950;20:661-664.
19. Khalili M, Vardanian AJ, Hamerski CM, Wang R, Bacchetti P, Roberts JP, et al. Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years. Clin Transplant 2006;20:1-9.
20. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R. Shuster JJ, Theriaque D, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004;10:1240-1247.
21. Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005;11:479-489.
22. Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 2003;9:1129-1144.
23. Kiernan JA. Histological and Histochemical Methods: Theory and Practice. 2nd ed. New York, NY: Pergamon Press; 1990.
24. Orrego H, Blendis LM, Crossley IR, Medline A, Macdonald A, Ritchie S, et al. Correlation of intrahepatic pressure with collagen in the Disse space and hepatomegaly in humans and in the rat. Gastroenterology 1981;80:546-556.
25. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-2618.